| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 09/21/2004 | US6794151 c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
| 09/21/2004 | US6794150 Detecting liver disorders in mammals; obtain sample, measure amount of marker, compare to control, diagnose liver disorder |
| 09/21/2004 | US6794149 GABA B receptors |
| 09/21/2004 | US6794145 Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| 09/21/2004 | US6794139 Composition or use in the diagnosis, treatment and prevention of tumors |
| 09/21/2004 | US6794132 Human antibodies |
| 09/21/2004 | US6794128 Methods of selecting internalizing antibodies |
| 09/21/2004 | US6793924 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated t cells and thereby inhibits t cell activation of b cells |
| 09/21/2004 | US6793921 Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers |
| 09/21/2004 | US6793920 Antithrombotic agent and anti-von willebrand factor monoclonal antibody |
| 09/16/2004 | WO2004078980A1 Nucleic acid and method of examining canceration using the nucleic acid |
| 09/16/2004 | WO2004078964A1 Method of producing hybridoma and utilization thereof |
| 09/16/2004 | WO2004078942A2 Endothelial cell specific antibodies and uses thereof |
| 09/16/2004 | WO2004078938A2 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 09/16/2004 | WO2004078937A2 Vectors used to create hybrid constant regions |
| 09/16/2004 | WO2004078928A2 T cell regulation |
| 09/16/2004 | WO2004078923A2 Pyk2 crystal structure and uses |
| 09/16/2004 | WO2004078909A2 Identification of antigen epitopes |
| 09/16/2004 | WO2004078907A2 Streptococcus pyogenes antigens |
| 09/16/2004 | WO2004078776A2 Ny-eso-1 peptides which bind to class ii molecules and uses thereof |
| 09/16/2004 | WO2004078215A2 Use of antibody conjugated deoxycytidine kinase for adept |
| 09/16/2004 | WO2004078209A1 Composition and method for the treatment and prevention of enteric bacterial infections |
| 09/16/2004 | WO2004078208A1 MEDICINAL USE OF MIP-3α INHIBITOR AND METHOD OF SCREENING BRAIN/NERVE CELL PROTECTIVE AGENT |
| 09/16/2004 | WO2004078204A1 Markers of blood barrier permeability and methods of using same |
| 09/16/2004 | WO2004078192A1 Use of tumor endothelial markers 1, 9 and 17 to promote angiogenesis |
| 09/16/2004 | WO2004078146A2 Trans-membrane-antibody induced inhibition of apoptosis |
| 09/16/2004 | WO2004078140A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| 09/16/2004 | WO2004078137A2 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 09/16/2004 | WO2004078135A2 LIGANDS THAT BIND TO THE AMYLOID-β PRECURSOR PEPTIDE AND RELATED MOLECULES AND USES THEREOF |
| 09/16/2004 | WO2004078123A2 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use |
| 09/16/2004 | WO2004078097A2 Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer |
| 09/16/2004 | WO2004069140A3 Antigen imitating extracellular areas of membrane proteins of type iii produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof |
| 09/16/2004 | WO2004055513A3 Use of cd137 antagonists for the treatment of tumors |
| 09/16/2004 | WO2004052278A3 Escape mutants of newcastle disease virus as marker vaccines |
| 09/16/2004 | WO2004050846A8 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| 09/16/2004 | WO2004050706A3 Regulatory t-cells |
| 09/16/2004 | WO2004047762A3 Methods for treating cancer using porimin as a target |
| 09/16/2004 | WO2004046189A3 Method for generating immunoglobulin genes |
| 09/16/2004 | WO2004046188A3 Anti-activated ras antibodies |
| 09/16/2004 | WO2004034979A3 Monoclonal antibodies specific for cariogenic bacteria |
| 09/16/2004 | WO2004020606A3 Method of resisting osteoclast formation |
| 09/16/2004 | WO2004016230A3 Identification of the endothelial receptor for the angiostatin kringle-5 |
| 09/16/2004 | WO2004013180A3 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| 09/16/2004 | WO2004005540A3 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases |
| 09/16/2004 | WO2003104432A3 Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| 09/16/2004 | WO2003099999A3 Generation and selection of protein library in silico |
| 09/16/2004 | WO2003096974A3 ORIENTIA TSUTSUGAMUSHI TRUNCATED RECOMBINANT OUTER MENBRANE PROTEIN (r47) AND (r56) VACCINES DIAGNOSTICS AND THERAPEUTICS FOR SCRUB TYPHUS AND HIV INFECTION |
| 09/16/2004 | WO2003089603A3 Cytokine receptor |
| 09/16/2004 | WO2003088898A3 Compositions and methods for the diagnosis and treatment of tumor |
| 09/16/2004 | WO2003083041A8 Cripto-specific antibodies |
| 09/16/2004 | WO2003060097A3 USE OF SOLUBLE Ϝδ T CELL RECEPTORS FOR REGULATING T CELL FUNCTION |
| 09/16/2004 | WO2003052048A3 Nucleic acid-associated proteins |
| 09/16/2004 | WO2003045318A3 Manipulation of cytokine levels using cd83 gene products |
| 09/16/2004 | WO2003043583A3 Treatment of immunological disorders using anti-cd30 antibodies |
| 09/16/2004 | WO2003040307A3 Heteromultimeric tnf ligand family members |
| 09/16/2004 | US20040181827 Plant Gntl sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I (GnTI) activity |
| 09/16/2004 | US20040181047 33 human secreted proteins |
| 09/16/2004 | US20040181044 for bone marrow recovery in treatment of radiation, chemical, or chemotherapeutic induced bone marrow aplasia or myelosuppression |
| 09/16/2004 | US20040181042 Antibody recognizing GM1 ganglioside-bound amyloid beta-protein and DNA encoding the antibody |
| 09/16/2004 | US20040181041 Fusion protein capable of inducing programmed cell death for use in treatment cell proliferative diseases and infection |
| 09/16/2004 | US20040181039 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| 09/16/2004 | US20040181037 Phosphatidyl serine receptors and uses thereof |
| 09/16/2004 | US20040180826 Novel receptor that causes cell death |
| 09/16/2004 | US20040180825 Semaphorin polypeptides |
| 09/16/2004 | US20040180817 Use of tumor necrosis factor alpha p75 receptor antagonist or endothelin receptor antagonist, converting enzyme inhibitor or neutralizing agent; reducting cerebral perfusion; method of identifying candidates |
| 09/16/2004 | US20040180418 Candida kefyr cytosine deaminase |
| 09/16/2004 | US20040180407 Novel G protein coupled receptor protein, DNA and its ligand |
| 09/16/2004 | US20040180387 Diagnosing ovarian cancer via presence of mesothelin/megakaryocyte potentiating factor polypeptides in urine of women; immunodiagnostics |
| 09/16/2004 | US20040180386 Using major histocompatibility complex polypeptides as tools in identifying lymphocyte binding sites; immunosuppression and tumor therapeutics |
| 09/16/2004 | US20040180367 Using anti-nucleic acid binding complex to detect viral sequences and diagnose transmissible spongiform encephalopathies (TSE) in animals and humans; veterinary medicine |
| 09/16/2004 | US20040180356 Comprises nucleotide sequences coding membrane proteins for use in diagnosis, prevention and treatment of cell proliferative, metabolic and inflammatory disorders |
| 09/16/2004 | US20040180354 Comprises polypeptides which are displayable on antigen presenting cells of immune system for use in prevention and treatment of infection and vaccine development; immunotherapy |
| 09/16/2004 | US20040180338 Mutated eukariotic transalation initiation factor 2 alpha kinase3, eif2ak3, in patients with neonatal insuluin-dependant diabetes and multiple epiphyseal dyslapsia (wolcott-rallison syndrome) |
| 09/16/2004 | US20040180337 Human extracellular signal regulated kinases |
| 09/16/2004 | US20040180335 Comprises nucleotide sequences coding transmembrane protein for diagnosis and treatment of epileptic, autoimmune and nervous system disorders |
| 09/16/2004 | US20040180057 Neutron capture therapy |
| 09/16/2004 | US20040180054 Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| 09/16/2004 | US20040180053 Binding protein |
| 09/16/2004 | US20040180052 Bind to AILIM (activation inducible lymphocyte immunomodulatory molecule, also referred to as ICOS (inducible co-stimulator); human monoclonal antibodies which bind to AILIM or a portion thereof; for treating disorders related to the delayed allergy |
| 09/16/2004 | US20040180051 Comprising an antibody against human tissue factor (human TF), for therapy of pulmonary thrombosis or deep venous thrombosis |
| 09/16/2004 | US20040180050 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease |
| 09/16/2004 | US20040180049 DR4 antibodies and uses thereof |
| 09/16/2004 | US20040180047 Autoantibodies specific for B7-H1 |
| 09/16/2004 | US20040180046 Bispecific molecules and uses thereof |
| 09/16/2004 | US20040180045 Orally administering to patient an immunoglobulin formulation comprising Cohn Fraction II+III in an amount sufficient to provide a clinically observable improvement in the disease symptoms |
| 09/16/2004 | US20040180002 production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, |
| 09/16/2004 | US20040180001 antitumor |
| 09/16/2004 | DE10327066A1 Bestimmung agonistischer Autoantikörper Determination of agonistic autoantibodies |
| 09/16/2004 | CA2796381A1 Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| 09/16/2004 | CA2518490A1 Endothelial cell specific antibodies and uses thereof |
| 09/16/2004 | CA2518237A1 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 09/16/2004 | CA2518119A1 Trans-membrane-antibody induced inhibition of apoptosis |
| 09/16/2004 | CA2517968A1 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 09/16/2004 | CA2517911A1 Composition and method for the treatment and prevention of enteric bacterial infections |
| 09/16/2004 | CA2517767A1 Ligands that bind to the amyloid-.beta. precursor peptide and related molecules and uses thereof |
| 09/16/2004 | CA2517519A1 Vectors used to create hybrid constant regions |
| 09/16/2004 | CA2517518A1 Streptococcus pyogenes antigens |
| 09/16/2004 | CA2517287A1 Regulation of t cells by lag-3 (cd223) |
| 09/16/2004 | CA2517158A1 Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer |
| 09/16/2004 | CA2517145A1 Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |